Your browser is no longer supported. Please, upgrade your browser.
PTCT [NASD]
PTC Therapeutics, Inc.
Index- P/E- EPS (ttm)-6.87 Insider Own0.60% Shs Outstand67.64M Perf Week-7.80%
Market Cap4.30B Forward P/E- EPS next Y-4.01 Insider Trans-75.68% Shs Float66.16M Perf Month-2.66%
Income-441.50M PEG- EPS next Q-0.92 Inst Own- Short Float7.14% Perf Quarter23.70%
Sales358.40M P/S12.00 EPS this Y-55.40% Inst Trans0.10% Short Ratio9.86 Perf Half Y32.50%
Book/sh7.55 P/B8.39 EPS next Y38.60% ROA-25.90% Target Price64.33 Perf Year18.81%
Cash/sh16.80 P/C3.77 EPS next 5Y-9.51% ROE-80.00% 52W Range30.79 - 70.82 Perf YTD3.82%
Dividend- P/FCF- EPS past 5Y-7.50% ROI-27.80% 52W High-10.53% Beta1.08
Dividend %- Quick Ratio4.80 Sales past 5Y64.80% Gross Margin95.10% 52W Low105.77% ATR2.59
Employees754 Current Ratio4.90 Sales Q/Q65.80% Oper. Margin- RSI (14)45.89 Volatility4.18% 3.95%
OptionableYes Debt/Eq1.94 EPS Q/Q3.00% Profit Margin- Rel Volume0.85 Prev Close63.05
ShortableYes LT Debt/Eq1.89 EarningsOct 29 AMC Payout- Avg Volume479.24K Price63.36
Recom2.20 SMA20-2.83% SMA50-0.84% SMA20018.44% Volume404,967 Change0.49%
Jan-05-21Upgrade Citigroup Neutral → Buy $67 → $85
Nov-30-20Downgrade RBC Capital Mkts Sector Perform → Underperform $45
Oct-30-20Downgrade Citigroup Buy → Neutral
Oct-28-20Initiated UBS Neutral $55
Oct-07-20Upgrade JP Morgan Neutral → Overweight $71
Aug-25-20Initiated Raymond James Outperform $63
Apr-09-20Upgrade Citigroup Neutral → Buy $71 → $67
Feb-20-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-20-20Downgrade Citigroup Buy → Neutral $55 → $71
Nov-12-19Initiated SunTrust Buy $78
May-13-19Upgrade BofA/Merrill Neutral → Buy $43 → $49
Apr-11-19Initiated Bernstein Outperform $48
Oct-03-18Upgrade BofA/Merrill Underperform → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $66
Jul-19-18Initiated Credit Suisse Outperform $49
Jun-18-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-04-18Downgrade Barclays Equal Weight → Underweight $24 → $26
Jan-29-18Resumed RBC Capital Mkts Sector Perform
Nov-16-17Upgrade JP Morgan Underweight → Neutral
Oct-26-17Downgrade BofA/Merrill Neutral → Underperform
Jan-14-21 08:00AM  
Jan-13-21 04:30PM  
Jan-11-21 06:30AM  
Jan-04-21 08:00AM  
Dec-31-20 02:57AM  
Dec-18-20 04:30PM  
Dec-09-20 08:00AM  
Dec-04-20 04:30PM  
08:00AM  
Nov-30-20 08:00AM  
Nov-25-20 03:01AM  
Nov-19-20 08:00AM  
Nov-18-20 08:00AM  
Nov-17-20 08:00AM  
Nov-16-20 08:00AM  
Oct-29-20 05:35PM  
04:01PM  
02:30PM  
Oct-28-20 04:30PM  
08:00AM  
Oct-26-20 08:00AM  
Oct-22-20 12:34PM  
08:00AM  
Oct-21-20 08:33AM  
Oct-20-20 12:58PM  
Oct-15-20 08:00AM  
Sep-28-20 01:00AM  
Sep-25-20 04:30PM  
Sep-24-20 08:00AM  
Sep-15-20 11:02AM  
Sep-14-20 03:20PM  
Sep-09-20 08:00AM  
Sep-08-20 08:00AM  
Sep-03-20 08:00AM  
Aug-27-20 09:39AM  
Aug-26-20 09:44AM  
08:00AM  
Aug-21-20 04:30PM  
Aug-18-20 05:07PM  
Aug-17-20 08:00AM  
Aug-10-20 07:07AM  
Aug-08-20 10:40AM  
Aug-07-20 02:46PM  
01:54PM  
Aug-06-20 08:00AM  
Aug-05-20 06:15PM  
04:01PM  
Jul-29-20 12:33PM  
Jul-22-20 08:00AM  
Jul-21-20 09:00AM  
Jul-20-20 07:45AM  
07:30AM  
Jul-12-20 08:14PM  
Jul-08-20 08:00AM  
Jun-29-20 02:04PM  
08:00AM  
Jun-23-20 04:05PM  
Jun-18-20 05:53PM  
10:25AM  
10:16AM  
Jun-17-20 07:30AM  
06:30AM  
Jun-12-20 04:30PM  
04:15PM  
Jun-10-20 08:00AM  
Jun-08-20 02:47AM  
Jun-01-20 08:00AM  
May-28-20 09:00AM  
May-27-20 07:04PM  
May-26-20 08:00AM  
May-21-20 04:27PM  
May-15-20 04:30PM  
May-06-20 04:30PM  
May-05-20 08:00AM  
Apr-30-20 06:35PM  
Apr-28-20 01:00AM  
Apr-23-20 12:32PM  
Apr-22-20 04:30PM  
Apr-17-20 08:00AM  
Apr-16-20 08:00AM  
Apr-09-20 10:16AM  
Apr-07-20 04:05PM  
Mar-30-20 06:06PM  
Mar-29-20 12:32PM  
Mar-25-20 09:04AM  
Mar-16-20 08:00AM  
Mar-11-20 04:30PM  
Mar-10-20 11:53AM  
Mar-04-20 09:40AM  
Mar-02-20 05:25PM  
04:01PM  
Feb-25-20 04:30PM  
Feb-24-20 12:30PM  
Feb-18-20 08:00AM  
Feb-17-20 04:30PM  
Feb-06-20 04:08PM  
10:41AM  
05:00AM  
Feb-03-20 04:30PM  
08:05AM  
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Klein Matthew B.Chief Development OfficerJan 15Option Exercise38.984,300167,61423,609Jan 20 04:10 PM
Klein Matthew B.Chief Development OfficerJan 15Sale69.094,300297,07819,309Jan 20 04:10 PM
Utter Christine MarieSVP, Finance & CAOJan 13Option Exercise16.393,28853,87420,029Jan 15 04:04 PM
Utter Christine MarieSVP, Finance & CAOJan 13Sale66.573,947262,75217,529Jan 15 04:04 PM
Hill Emily LuisaChief Financial OfficerJan 08Option Exercise23.5626,033613,40934,622Jan 12 04:15 PM
Klein Matthew B.Chief Development OfficerJan 08Option Exercise38.985,500214,39024,809Jan 12 04:17 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 08Option Exercise27.051,30035,1653,688Jan 12 04:18 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 08Sale69.001,30089,7002,388Jan 12 04:18 PM
Klein Matthew B.Chief Development OfficerJan 08Sale69.715,500383,41019,309Jan 12 04:17 PM
Hill Emily LuisaChief Financial OfficerJan 08Sale69.7526,0331,815,80224,122Jan 12 04:15 PM
Klein Matthew B.Chief Development OfficerJan 07Option Exercise38.983,886151,47623,195Jan 08 05:12 PM
Klein Matthew B.Chief Development OfficerJan 07Sale68.983,886268,05619,309Jan 08 05:12 PM
Boulding Mark ElliottExec. VP and CLOJan 05Sale62.3777248,15038,952Jan 07 05:05 PM
Hill Emily LuisaChief Financial OfficerJan 05Sale62.3728817,96313,322Jan 07 05:02 PM
Pauwels EricChief Business OfficerJan 05Sale62.371,06766,54927,080Jan 07 04:59 PM
Peltz Stuart WalterChief Executive OfficerJan 05Sale62.3766641,53811,754Jan 07 04:57 PM
Peltz Stuart WalterChief Executive OfficerJan 05Sale62.371,40287,44354,683Jan 07 04:57 PM
Utter Christine MarieSVP, Finance & CAOJan 05Sale62.3731619,7099,488Jan 07 04:55 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 05Sale62.371247,7341,788Jan 07 04:54 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 05Sale62.3750231,31026,587Jan 07 04:54 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 04Option Exercise10.856006,5102,512Jan 06 04:06 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 04Option Exercise20.79103,4382,150,35975,214Jan 06 04:06 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 04Sale60.6560036,3901,912Jan 06 04:06 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 04Sale60.58103,4386,266,16727,089Jan 06 04:06 PM
Peltz Stuart WalterChief Executive OfficerDec 30Option Exercise31.74285,7189,067,681225,866Dec 31 04:06 PM
Peltz Stuart WalterChief Executive OfficerDec 30Sale61.74285,71817,641,45956,085Dec 31 04:06 PM
Reeve EmmaDirectorDec 15Option Exercise33.021,02833,9452,678Dec 16 04:09 PM
Reeve EmmaDirectorDec 14Option Exercise33.021,97265,1152,650Dec 16 04:09 PM
Reeve EmmaDirectorDec 14Sale68.001,972134,0961,650Dec 16 04:09 PM
Okey StephanieDirectorDec 08Sale62.5268742,954963Dec 10 04:09 PM
Peltz Stuart WalterChief Executive OfficerDec 07Option Exercise16.6820,017333,95463,675Dec 09 07:52 PM
Peltz Stuart WalterChief Executive OfficerDec 07Option Exercise22.66348,4177,894,942248,877Dec 09 07:54 PM
Peltz Stuart WalterChief Executive OfficerDec 07Sale61.00348,41721,254,76656,085Dec 09 07:54 PM
Peltz Stuart WalterChief Executive OfficerDec 07Sale61.4220,0171,229,48456,085Dec 09 07:52 PM
Almstead Neil GregoryChief Technical Ops OfficerNov 04Option Exercise11.2324,062270,21648,964Nov 06 04:27 PM
Jacobson Allan StevenDirectorNov 04Option Exercise10.8520,000217,00023,498Nov 06 04:30 PM
Utter Christine MarieSVP, Finance & CAONov 04Option Exercise30.9731,758983,52620,187Nov 06 04:35 PM
Peltz Stuart WalterChief Executive OfficerNov 04Option Exercise25.3838,328972,95520,599Nov 06 04:40 PM
Peltz Stuart WalterChief Executive OfficerNov 04Sale60.0049,3652,961,90012,178Nov 06 04:40 PM
Utter Christine MarieSVP, Finance & CAONov 04Sale60.0631,7581,907,4049,562Nov 06 04:35 PM
Jacobson Allan StevenDirectorNov 04Sale60.0020,0001,200,0003,498Nov 06 04:30 PM
Almstead Neil GregoryChief Technical Ops OfficerNov 04Sale60.0024,0621,443,72027,089Nov 06 04:27 PM
Pauwels EricChief Business OfficerNov 03Sale56.506,194349,96127,647Nov 05 04:25 PM
Peltz Stuart WalterChief Executive OfficerNov 02Option Exercise10.8550,000542,500106,085Nov 03 07:52 PM
Peltz Stuart WalterChief Executive OfficerNov 02Sale53.6650,0002,682,95456,085Nov 03 07:52 PM
SOUTHWELL DAVID PDirectorOct 16Option Exercise11.0227,000297,51016,650Oct 20 04:34 PM
Jacobson Allan StevenDirectorOct 16Sale51.295,000256,4503,498Oct 20 04:35 PM
SOUTHWELL DAVID PDirectorOct 16Sale51.5427,0001,391,5441,650Oct 20 04:34 PM
Peltz Stuart WalterChief Executive OfficerOct 07Option Exercise11.1171,104789,785104,260Oct 09 04:20 PM
Peltz Stuart WalterChief Executive OfficerOct 07Sale53.3871,1043,795,26256,085Oct 09 04:20 PM
Utter Christine MarieSVP, Finance & CAOOct 06Option Exercise18.012,50045,02512,062Oct 07 08:59 PM
Peltz Stuart WalterChief Executive OfficerOct 06Option Exercise11.01124,3511,368,902107,910Oct 07 09:01 PM
Peltz Stuart WalterChief Executive OfficerOct 06Sale50.12124,3516,233,08356,085Oct 07 09:01 PM
Utter Christine MarieSVP, Finance & CAOOct 06Sale50.082,500125,2089,562Oct 07 08:59 PM
Utter Christine MarieSVP, Finance & CAOOct 05Option Exercise11.237878,83810,349Oct 07 08:59 PM
Peltz Stuart WalterChief Executive OfficerOct 05Option Exercise10.8555,460601,741110,645Oct 07 09:01 PM
Peltz Stuart WalterChief Executive OfficerOct 05Sale50.0055,4602,773,00056,085Oct 07 09:01 PM
Utter Christine MarieSVP, Finance & CAOOct 05Sale48.6878738,3119,562Oct 07 08:59 PM
Peltz Stuart WalterChief Executive OfficerJul 15Option Exercise10.85100,0001,085,000106,085Jul 17 04:30 PM
Peltz Stuart WalterChief Executive OfficerJul 15Sale55.70100,0005,570,15156,085Jul 17 04:30 PM
Boulding Mark ElliottExec. VP and CLOJul 07Option Exercise15.1030,625462,56957,224Jul 09 04:08 PM
Boulding Mark ElliottExec. VP and CLOJul 07Sale55.1230,6251,688,03739,724Jul 09 04:08 PM
Utter Christine MarieSVP, Finance & CAOJul 06Option Exercise16.393,28853,87412,062Jul 08 04:04 PM
Utter Christine MarieSVP, Finance & CAOJul 06Sale53.703,288176,5649,562Jul 08 04:04 PM
Hill Emily LuisaChief Financial OfficerJun 29Sale52.502,581135,50313,610Jul 01 04:06 PM
Svoronos DawnDirectorJun 11Sale48.3636417,60326,286Jun 12 04:04 PM
Peltz Stuart WalterChief Executive OfficerMay 20Option Exercise10.8533,788366,60089,873May 22 04:05 PM
Peltz Stuart WalterChief Executive OfficerMay 20Sale50.0033,7881,689,40056,085May 22 04:05 PM
Peltz Stuart WalterChief Executive OfficerMay 18Option Exercise10.856,28468,18162,369May 20 04:07 PM
Peltz Stuart WalterChief Executive OfficerMay 18Sale50.126,284314,97956,085May 20 04:07 PM
Peltz Stuart WalterChief Executive OfficerMay 05Option Exercise10.85109,9281,192,719166,013May 07 03:44 PM
Peltz Stuart WalterChief Executive OfficerMay 05Sale50.34109,9285,533,59256,085May 07 03:44 PM
Jacobson Allan StevenDirectorApr 20Option Exercise10.8517,900194,21526,398Apr 21 04:13 PM
Jacobson Allan StevenDirectorApr 20Sale51.0417,900913,5588,498Apr 21 04:13 PM
Jacobson Allan StevenDirectorApr 17Option Exercise10.852,10022,78510,598Apr 21 04:13 PM
Utter Christine MarieSVP, Finance & CAOApr 17Option Exercise18.012,14538,63111,449Apr 21 04:15 PM
Utter Christine MarieSVP, Finance & CAOApr 17Sale50.002,145107,2509,304Apr 21 04:15 PM
Jacobson Allan StevenDirectorApr 17Sale50.162,100105,3328,498Apr 21 04:13 PM
Utter Christine MarieSVP, Finance & CAOApr 03Option Exercise11.237878,83810,091Apr 07 04:05 PM
Utter Christine MarieSVP, Finance & CAOApr 03Sale44.3178734,8729,304Apr 07 04:05 PM
SCHMERTZLER MICHAELDirectorMar 16Buy32.4810,000324,846100,066Mar 18 05:05 PM
Souza MarcioChief Operating OfficerFeb 10Option Exercise12.926258,0757,369Feb 12 04:09 PM
Souza MarcioChief Operating OfficerFeb 10Sale53.9262533,7006,744Feb 12 04:09 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 06Option Exercise10.8550,000542,50073,987Feb 07 04:41 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 06Sale55.004,040222,2001,912Feb 07 04:41 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 06Sale55.0050,0002,750,00027,089Feb 07 04:41 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 05Sale55.0040522,2755,952Feb 07 04:41 PM